Humoral p53 antibody response is a prognostic parameter in ovarian cancer

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 875-878

  Mayerhofer, Klaus ^a   Tempfer, Clemens ^a   Kucera, Elisabeth ^a   Hefler, Lukas ^a   Zeisler, Harald ^a   Kainz, Christian ^a   Zeillinger, Robert ^a   Sliutz, Gerhard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ovarian cancer; p53 gene; Prognosis; Serum p53 antibodies

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BENIGN TUMOR; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032897838     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
2. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancer. Science 253: 44-53, 1991.
3. Lane DP: p53, guardian of genome. Nature 358: 15-16, 1992.
4. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7441-7445, 1992.
5. Davidoff AM, Herndon JE, Glover NS, Kerns BJM, Pence JC, Iglehart JD and Marks JR: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 254-264, 1991.
6. Tominaga O, Hamelin R, Trouvat V, Salmon RJ, Lesee G, Thomas G and Remvikos Y: Frequently elevated content of immunochemically defined wild- type p53 protein in colorectal adenomas. Oncogene 8: 2653-2658, 1993.
7. Williams AC, Browne SJ, Yeudal WA, Paterson IC, Marshall CJ, Lane DP and Paraskeva C: Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma. Oncogene 8: 3063-3072, 1993.
8. Lu X and Lane DP: Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75: 765-778, 1993.
9. Sarnow P, Ho YS, Williams J and Levine AJ: Adenovirus E1 b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28: 387-394, 1982.
10. Oren M, Reich NC and Levine AJ: Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny. Mol Cell Biol 2: 443-449, 1982.
11. Midgley C and Lane DP: p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189, 1997.
12. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F and Soussi T: The immune response to p53 in breast cancer patients is directed against immunudominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384, 1992.
13. Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in the sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
14. Davidoff AM, Iglehart JD and Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89: 3439-3442, 1992.
15. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M and Leinster SJ: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69: 1115-1119, 1994.
16. Houbiers JGA, van der Burg SH, van de Watering LMG, Tollenaar RAEM, Brand A, van de Velde CJH and Melief CJM: Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 637-641, 1995.
17. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
18. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480-487, 1994.
19. Porzsolt F, Schmid M, Hoher D, Muche R, Gaus W and Montenarh M: Biologic relevance of auto-antibodies against p53 in patients with metastatic breast cancer. Onkologie 17: 402-408, 1994.
20. Labreque S, Naor N, Thomson D and Matlashewski G: Analysis of the ani-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471, 1993.
21. Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, Bevilacqua G, Genazani AR: Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res 16: 3519-3523, 1996.
22. Yashar CM, Gercel Taylor C, Gibb RK, Weeks JW, Taylor DD: Identification of a unique form of p53 in human cord blood associated with the development of maternal autoantibodies. Am J Repr Immun 39: 368-375, 1998.
23. Angelopoulou K and Diamandis EP: Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer 33: 115-121, 1997.
24. Angelopoulou K, Rosen B, Stratis M, Yu HE, Solomou M and Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 78: 2146-2152, 1996.
25. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 53: 457-481, 1958.
26. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Caron De Fromentel C, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A Peyrat JP, Janin N, Bressac B and Soussi T: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872-5876, 1993.
27. Marx D, Uebel T, Schauer A, Kuhn W, Meden H: Association of serum autoantibodies to tumor-suppressor gene p53 in patients with ovarian cancer according to status of the disease. Oncol Rep 4: 1157-1160, 1997.
28. Crawford LV, Pim DC and Lamb P: The cellular protein p53 in human tumours. Mol Biol Med 2: 261-272, 1984.
29. Marxsen J, Schmiegel W, Roder C, Harder R, Juhl H, Henne-Bruns D, Kremer B and Kalthoff H: Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 70: 1031-1034, 1994.
30. Vojtesek B, Bartek J, Midgley CA and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244, 1992.